Literature DB >> 21327023

Safety assessment of probiotics for human use.

Mary Ellen Sanders1, Louis M A Akkermans, Dirk Haller, Cathy Hammerman, James Heimbach, Gabriele Hörmannsperger, Geert Huys, Dan D Levy, Femke Lutgendorff, David Mack, Phoukham Phothirath, Gloria Solano-Aguilar, Elaine Vaughan.   

Abstract

The safety of probiotics is tied to their intended use, which includes consideration of potential vulnerability of the consumer or patient, dose and duration of consumption, and both the manner and frequency of administration. Unique to probiotics is that they are alive when administered, and unlike other food or drug ingredients, possess the potential for infectivity or in situ toxin production. Since numerous types of microbes are used as probiotics, safety is also intricately tied to the nature of the specific microbe being used. The presence of transferable antibiotic resistance genes, which comprises a theoretical risk of transfer to a less innocuous member of the gut microbial community, must also be considered. Genetic stability of the probiotic over time, deleterious metabolic activities, and the potential for pathogenicity or toxicogenicity must be assessed depending on the characteristics of the genus and species of the microbe being used. Immunological effects must be considered, especially in certain vulnerable populations, including infants with undeveloped immune function. A few reports about negative probiotic effects have surfaced, the significance of which would be better understood with more complete understanding of the mechanisms of probiotic interaction with the host and colonizing microbes. Use of readily available and low cost genomic sequencing technologies to assure the absence of genes of concern is advisable for candidate probiotic strains. The field of probiotic safety is characterized by the scarcity of studies specifically designed to assess safety contrasted with the long history of safe use of many of these microbes in foods.

Entities:  

Keywords:  FDA; Health Canada; PROSAFE; QPS; antibiotic resistance; bifidobacterium; lactobacillus; probiotic; safety

Mesh:

Year:  2010        PMID: 21327023      PMCID: PMC3023597          DOI: 10.4161/gmic.1.3.12127

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  183 in total

1.  Genetic basis of tetracycline and minocycline resistance in potentially probiotic Lactobacillus plantarum strain CCUG 43738.

Authors:  Geert Huys; Klaas D'Haene; Jean Swings
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Safety assessment of Lactobacillus strains: presence of putative risk factors in faecal, blood and probiotic isolates.

Authors:  Satu Vesterlund; Vanessa Vankerckhoven; Maija Saxelin; Herman Goossens; Seppo Salminen; Arthur C Ouwehand
Journal:  Int J Food Microbiol       Date:  2007-03-01       Impact factor: 5.277

Review 3.  Lactate and short chain fatty acid production in the human colon: implications for D-lactic acidosis, short-bowel syndrome, antibiotic-associated diarrhoea, colonic cancer, and inflammatory bowel disease.

Authors:  H Hove
Journal:  Dan Med Bull       Date:  1998-02

4.  Effect of metformin on survival rate in experimental sepsis.

Authors:  V Gras; B Bouffandeau; P H Montravers; J D Lalau
Journal:  Diabetes Metab       Date:  2006-04       Impact factor: 6.041

Review 5.  AAVP Symposium: new approaches in the study of animal parasites.

Authors:  T R Klei; S R Chirgwin; G Solano-Aguilar; T Shea-Donohue; K Madden; H Dawson; T Ledbetter; J Urban; L C Gasbarre; T Sonstegard; C P Van Tassell; R Araujo
Journal:  Vet Parasitol       Date:  2004-10-28       Impact factor: 2.738

6.  Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis.

Authors:  C Farina; M Arosio; M Mangia; F Moioli
Journal:  J Clin Gastroenterol       Date:  2001-09       Impact factor: 3.062

7.  Taxonomic and strain-specific identification of the probiotic strain Lactobacillus rhamnosus 35 within the Lactobacillus casei group.

Authors:  Sophie Coudeyras; Hélène Marchandin; Céline Fajon; Christiane Forestier
Journal:  Appl Environ Microbiol       Date:  2008-03-07       Impact factor: 4.792

8.  Numbers and strains of lactobacilli in some probiotic products.

Authors:  Valérie Coeuret; Micheline Gueguen; Jean Paul Vernoux
Journal:  Int J Food Microbiol       Date:  2004-12-15       Impact factor: 5.277

9.  Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Authors:  Li Wen; Ruth E Ley; Pavel Yu Volchkov; Peter B Stranges; Lia Avanesyan; Austin C Stonebraker; Changyun Hu; F Susan Wong; Gregory L Szot; Jeffrey A Bluestone; Jeffrey I Gordon; Alexander V Chervonsky
Journal:  Nature       Date:  2008-09-21       Impact factor: 49.962

10.  Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host.

Authors:  Justin L Sonnenburg; Christina T L Chen; Jeffrey I Gordon
Journal:  PLoS Biol       Date:  2006-11       Impact factor: 8.029

View more
  119 in total

1.  Feasibility of Genome-Wide Screening for Biosafety Assessment of Probiotics: A Case Study of Lactobacillus helveticus MTCC 5463.

Authors:  S Senan; J B Prajapati; C G Joshi
Journal:  Probiotics Antimicrob Proteins       Date:  2015-12       Impact factor: 4.609

2.  Supercritical CO2 interpolymer complex encapsulation improves heat stability of probiotic bifidobacteria.

Authors:  M S Thantsha; P W Labuschagne; C I Mamvura
Journal:  World J Microbiol Biotechnol       Date:  2013-08-30       Impact factor: 3.312

Review 3.  Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease.

Authors:  Collin L Ellis; John C Rutledge; Mark A Underwood
Journal:  Gut Microbes       Date:  2010 Nov-Dec

Review 4.  Bioengineered probiotics, a strategic approach to control enteric infections.

Authors:  Mary Anne Roshni Amalaradjou; Arun K Bhunia
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

Review 5.  Lactocepin as a protective microbial structure in the context of IBD.

Authors:  Gabriele Hörmannsperger; Marie-Anne von Schillde; Dirk Haller
Journal:  Gut Microbes       Date:  2013-01-18

6.  Is "processed" a four-letter word? The role of processed foods in achieving dietary guidelines and nutrient recommendations.

Authors:  Johanna T Dwyer; Victor L Fulgoni; Roger A Clemens; David B Schmidt; Marjorie R Freedman
Journal:  Adv Nutr       Date:  2012-07-01       Impact factor: 8.701

7.  Antibiotic resistance, biochemical typing, and PFGE typing of Bifidobacterium strains commonly used in probiotic health foods.

Authors:  Feili Xu; Junping Wang; Yunchang Guo; Ping Fu; Huawei Zeng; Zhigang Li; Xiaoyan Pei; Xiumei Liu; Shuo Wang
Journal:  Food Sci Biotechnol       Date:  2018-02-12       Impact factor: 2.391

8.  Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice.

Authors:  Hannah Grazul; L Leann Kanda; David Gondek
Journal:  Gut Microbes       Date:  2016-03-10

9.  Evaluation of Probiotic Potential of Bacteriocinogenic Lactic Acid Bacteria Strains Isolated from Meat Products.

Authors:  Izildinha Moreno; Elza Teresinha Grael Marasca; Patrícia Blumer Zacarchenco Rodrigues de Sá; Josiane de Souza Moitinho; Miriam Gonçalves Marquezini; Márcia Regina Cucatti Alves; Renata Bromberg
Journal:  Probiotics Antimicrob Proteins       Date:  2018-12       Impact factor: 4.609

10.  Assessing the Safety and Efficacy of Lactobacillus plantarum MTCC 5690 and Lactobacillus fermentum MTCC 5689 in Colitis Mouse Model.

Authors:  Diwas Pradhan; Rajbir Singh; Ashish Tyagi; Rashmi H M; Virender K Batish; Sunita Grover
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.